Abstract

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans

Willis, J. R. Prabhakaran, M. Muthui, M. Naidoo, A. Sincomb, T. Wu, W. Cottrell, C. A. Landais, E. deCamp, A. C. Keshavarzi, N. R. Kalyuzhniy, O. Lee, J. H. Murungi, L. M. Ogonda, W. A. Yates, N. L. Corcoran, M. M. Phulera, S. Musando, J. Tsai, A. Lemire, G. Sein, Y. Muteti, M. Alamuri, P. Bohl, J. A. Holman, D. Himansu, S. Leav, B. Reuter, C. Lin, L. A. Ding, B. He, C. Straus, W. L. MacPhee, K. J. Regadas, I. Nyabundi, D. V. Chirchir, R. Anzala, O. Kimotho, J. N. Kibet, C. Greene, K. Gao, H. Beatman, E. Benson, K. Laddy, D. Brown, D. M. Bronson, R. Jean-Baptiste, J. Gajjala, S. Rikhtegaran-Tehrani, Z. Benner, A. Ramaswami, M. Lu, D. Alavi, N. Amirzehni, S. Kubitz, M. Tingle, R. Georgeson, E. Phelps, N. Adachi, Y. Liguori, A. Flynn, C. McKenney, K. Zhou, X. Owuor, D. C. Owuor, S. A. Kim, S. Y. Duff, M. Kim, J. Y. Gibson, G. Baboo, S. Diedrich, J. Schiffner, T. Shields, M. Matsoso, M. Santos, J. Syvertsen, K. Kennedy, A. Schroeter, M. Vekemans, J. Yates, J. R, 3rd Paulson, J. C. Hyrien, O. McDermott, A. B. Maenetje, P. Nyombayire, J. Karita, E. Ingabire, R. Edward, V. Muturi-Kioi, V. Maenza, J. Shapiro, A. E. McElrath, M. J. Edupuganti, S. Taylor, B. S. Diemert, D. Ozorowski, G. Koup, R. A. Montefiori, D. Ward, A. B. Karlsson Hedestam, G. B. Tomaras, G. Hunt, D. J. Muema, D. Sok, D. Laufer, D. S. Andrews, S. F. Nduati, E. W. Schief, W. R.
Science. 2025; 389eadr8382

Permanent descriptor

https://doi.org/10.1126/science.adr8382

A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI G002 in the United States and IAVI G003 in Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI G002). The vaccines were generally safe and well tolerated, except that 18% of IAVI G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM; heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development; and elicited antibodies exhibited precise bnAb structural mimicry. The results establish clinical proof of concept that heterologous boosting can advance bnAb precursor maturation and demonstrate bnAb priming in Africa, where the HIV burden is highest.